TNAs, or therapeutic nucleic acids, are nucleic acids or closely related compounds that are used to cure disease. TNAs come in a variety of shapes and sizes, but they all have the same mode of action: sequence specific recognition of endogenous nucleic acids via Watson–Crick base pairing. The growing number of FDA-approved nucleic acid therapies shows that diseases can be treated in vivo by addressing their genetic blueprints. Because they target proteins rather than the underlying reasons, traditional therapies typically have transitory therapeutic results. Nucleic acid treatments, on the other hand, can achieve long-lasting or even curative effects by inhibiting, replacing, or altering genes. However, delivery strategies that improve stability, enable internalisation, and boost target affinity are required for clinical translation. Synthetic biology, systems biology, computational biology, bioinformatics, and nanotechnology, among other fields, have accelerated progress and established a new paradigm for nucleic acids in therapy.
Title : Actinobacteria as eco-friendly biopesticides: A sustainable approach to pest management
Saba Siddiqui, Integral University, India
Title : Biotech innovations: Bioengineering potential for novel biomanufacturing systems
Murray Moo Young, University of Waterloo, Canada
Title : Targeting noncanonical epitopes in anti-cancer immunotherapy
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Application of convolutional neural networks in classification of GBM for enhanced prognosis
Rithik Samanthula, Thomas Jefferson High School for Science and Technology, United States
Title : Stem cell therapy: An affordable healthcare therapy for various diseases
Anant Marathe, Total Potential Cells (P) Ltd, India
Title : Flu vaccines available in Italy for the youth population
Davide Frumento, RomaTre University, Italy